Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in
CD20-Positive Posttransplant Lymphoproliferative Disorder
Table 1
Patient’s baseline characteristics.
FcγRIIIA p.158 evaluated
FcγRIIIA p.158 non-F-carrier
FcγRIIIA p.158 F carrier
Number of patients
25
11
14
Age/years: median (range)
51 (18–74)
51 (18–74)
48 (23–68)
n.s†
Male
17/25
8/11
9/14
n.s.
Transplant type
Kidney
11/25
6/11
5/14
n.s.
Liver
7/25
2/11
5/14
Heart
6/25
3/11
3/14
Kidney + pancreas
1/25
0/11
1/14
Time from transplantation to PTLD/years: median (range)
3.9 (0.4–25.3)
3.7 (0.4–25.3)
6.1 (0.4–15.4)
n.s†
More than 1 year
20/25
9/11
11/14
n.s
Histology
Polymorphic
2/25
1/11
1/14
n.s.
Monomorphic
23/25
10/11
13/14
Burkitt
1/23
0/10
1/13
DLBCL
17/23
7/10
10/13
Other B cell
5/23
3/10
2/13
EBV association
12/25
6/11
6/14
n.s.
Ann Arbor stage
I/II
6/25
2/11
4/14
n.s.
III/IV
19/25
9/11
10/14
LDH (upper limit of normal 240 U/L)
Elevated*
13/24*
8/11
5/13*
n.s.
Disease manifestations
Nodal disease
15/25
5/11
10/14
n.s.
Extranodal disease
20/25
10/11
10/14
n.s.
ECOG performance status
<2
18/25
7/11
11/14
n.s.
≥2
7/25
4/11
3/14
DLBCL indicates diffuse large B cell lymphoma; EBV: Epstein-Barr virus; and ECOG: Eastern Cooperative Oncology Group. *Parameter not evaluated in the missing patients; †Mann-Whitney test.
